Pfizer vaccinations for 16 to 39-year-olds is welcome news. But AstraZeneca remains a good option

Importantly, given what we know about the high rates of COVID infections in younger people, and the significant role they're playing in transmission, this is good news. Boosting vaccination rates in this group will be a crucial step towards controlling the virus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2WaD7Ru
via IFTTT